The General Court of the European Union has dismissed in its entirety Illumina’s appeal against the European Commission’s decisions of April 2021 to declare itself competent to analyse the merger between Illumina and Grail, in a judgment delivered on Wednesday 13 July (Case T-123/22) (see EUROPE B12824A11).
In the absence of turnover exceeding the relevant European thresholds, the acquisition of the US biotech company Grail, which develops cancer screening tests, by the US genome...